Teva Pharmaceutical Industries Ltd Adr (TEVA)

May 18, 2026

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact - GlobeNewswire Inc.

May 18, 2026

May 17, 2026

symbol__ Stock Quote Price and Forecast - CNN

May 17, 2026

May 17, 2026

A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After A Strong Year And Recent Pullback - Sahm

May 17, 2026

May 15, 2026

Earnings call transcript: Teva Q1 2026 earnings beat forecasts - Investing.com

May 15, 2026

May 15, 2026

Earnings call transcript: Teva Q1 2026 earnings beat forecasts By Investing.com - Investing.com Canada

May 15, 2026

May 14, 2026

TEVA Stock Price, Quote & Chart | TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) - ChartMill

May 14, 2026

May 13, 2026

How Investors May Respond To Teva (TEVA) Showcasing CNS Growth And Emalex Deal At Key Conferences - Sahm

May 13, 2026

May 12, 2026

Earnings call transcript: Teva beats Q1 2026 expectations with strong growth - Investing.com

May 12, 2026

May 12, 2026

Earnings call transcript: Teva beats Q1 2026 expectations with strong growth By Investing.com - Investing.com Australia

May 12, 2026

May 08, 2026

A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Strong Q1 2026 And Biopharma Pipeline Progress - Sahm

May 08, 2026

May 06, 2026

Is It Too Late To Reassess Teva Pharmaceutical Industries (TEVA) After Its Strong Multi Year Rally? - Sahm

May 06, 2026

May 05, 2026

Reddit Upgraded, Spotify Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

May 05, 2026

May 03, 2026

Why Teva (TEVA) Is Up 14.1% After Strong Q1 Profitability And Neuroscience Pivot News - Sahm

May 03, 2026

May 01, 2026

Teva Pharmaceutical (TEVA) Q1 EPS Of US$0.32 Tests Bullish Profitability Narrative - Sahm

May 01, 2026

Apr 30, 2026

Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan - Sahm

Apr 30, 2026

Apr 30, 2026

Teva Pharmaceutical Indus Q1 2026 Earnings Call Transcript - Sahm

Apr 30, 2026

Apr 30, 2026

Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets - Sahm

Apr 30, 2026

Apr 29, 2026

Teva’s Home Ground Schizophrenia Push And What It Could Mean For Investors - Sahm

Apr 29, 2026

Apr 29, 2026

Teva Enjoys Strong Start to 2026 Thanks to Strong Momentum in Branded Portfolio - Morningstar

Apr 29, 2026

Apr 29, 2026

Earnings call transcript: Teva beats Q1 2026 forecasts, stock surges 7.5% - Investing.com

Apr 29, 2026

Apr 27, 2026

Intel Upgraded, Toyota Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Apr 27, 2026

Apr 23, 2026

Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - GlobeNewswire Inc.

Apr 23, 2026

Apr 22, 2026

Is It Too Late To Reassess Teva (TEVA) After Its 118.5% One-Year Surge? - Sahm

Apr 22, 2026

Apr 19, 2026

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After The Home Ground Schizophrenia Platform Launch - Sahm

Apr 19, 2026

Apr 18, 2026

Teva- Pharmaceutical Industries Ltd.ADR (TEVA) News, Articles, Events & Latest Updates - Stocktwits

Apr 18, 2026

Apr 16, 2026

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners - Sahm

Apr 16, 2026

Apr 14, 2026

Teva Pharmaceutical (ADR) stock (US88162G1031): Why generic drug execution is suddenly worth a close - AD HOC NEWS

Apr 14, 2026

Apr 14, 2026

Does Biosimilar Wins in Osteoporosis and Allergy Care Change The Bull Case For Teva (TEVA)? - Sahm

Apr 14, 2026

Apr 12, 2026

A Look At Teva Pharmaceutical Industries (TEVA) Valuation After Recent Biosimilar Regulatory Milestones - Sahm

Apr 12, 2026

Apr 07, 2026

Target Upgraded, Robinhood Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Apr 07, 2026

Apr 05, 2026

How Investors Are Reacting To Teva (TEVA) Advancing Its Biosimilar Pipeline With New FDA and EMA Milestones - Sahm

Apr 05, 2026

Apr 03, 2026

Assessing Teva Pharmaceutical Industries (TEVA) Valuation After New Biosimilar Approvals And Pipeline Progress - Sahm

Apr 03, 2026

Apr 02, 2026

Missile Strike Tests Teva Supply Resilience And Biosimilar Growth Plans - Sahm

Apr 02, 2026

Apr 01, 2026

Price to sales ratio of Teva Pharmaceutical Industries Limited Sponsored ADR – BSESOF:TEV - TradingView

Apr 01, 2026

Mar 30, 2026

Teva’s New Biosimilars Test Growth Plan And Earnings Reshaping Potential - Sahm

Mar 30, 2026

Mar 27, 2026

ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView

Mar 27, 2026

Mar 25, 2026

How Investors May Respond To Teva (TEVA) Advancing TEV ‘325 In Biologics For Inflammatory Diseases - Sahm

Mar 25, 2026

Mar 24, 2026

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Recent Share Price Weakness - Sahm

Mar 24, 2026

Mar 19, 2026

Teva Pharmaceutical Industries Limited Sponsored ADR Trade Ideas — LS:883035 - TradingView

Mar 19, 2026

Mar 19, 2026

Teva Releases Q1 2026 Aide Memoire - Sahm

Mar 19, 2026

Mar 18, 2026

Will Teva’s (TEVA) Olanzapine LAI Milestone and Legal Win Change Its Innovation-Led Narrative? - Sahm

Mar 18, 2026

Mar 17, 2026

Tesla Upgraded, Super Micro Computer Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Mar 17, 2026

Mar 11, 2026

How Teva’s Blackstone-Backed ‘Pivot to Growth’ Strategy Could Reshape Teva Pharmaceutical Industries (TEVA) Investors - Sahm

Mar 11, 2026

Mar 10, 2026

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Pivot To Growth Update At Leerink Conference - Sahm

Mar 10, 2026